1. Home
  2. TBBK vs SYRE Comparison

TBBK vs SYRE Comparison

Compare TBBK & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Bancorp Inc

TBBK

The Bancorp Inc

HOLD

Current Price

$59.56

Market Cap

2.4B

Sector

Finance

ML Signal

HOLD

Logo Spyre Therapeutics Inc.

SYRE

Spyre Therapeutics Inc.

HOLD

Current Price

$64.21

Market Cap

4.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBBK
SYRE
Founded
1999
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
4.0B
IPO Year
2005
2015

Fundamental Metrics

Financial Performance
Metric
TBBK
SYRE
Price
$59.56
$64.21
Analyst Decision
Buy
Strong Buy
Analyst Count
3
9
Target Price
$69.00
$77.78
AVG Volume (30 Days)
420.5K
898.2K
Earning Date
04-23-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
14.69
N/A
EPS
4.92
N/A
Revenue
$141,147,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.16
N/A
P/E Ratio
$12.09
N/A
Revenue Growth
20.85
N/A
52 Week Low
$42.86
$12.04
52 Week High
$81.65
$75.00

Technical Indicators

Market Signals
Indicator
TBBK
SYRE
Relative Strength Index (RSI) 67.89 80.96
Support Level $50.85 $15.23
Resistance Level $71.63 N/A
Average True Range (ATR) 1.67 4.11
MACD 0.90 1.44
Stochastic Oscillator 93.49 66.69

Price Performance

Historical Comparison
TBBK
SYRE

About TBBK The Bancorp Inc

The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, Credit Solutions (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Credit Solutions includes REBL (real estate bridge lending), comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Share on Social Networks: